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Abstract Purpose: To investigate
differences in cytokine/chemokine
release in response to lipoteichoic
acid (LTA) or lipopolysaccharide
(LPS) and contributing cellular
mechanisms, in order to improve
understanding of the pathogenesis of
sepsis. Methods: Levels of cyto-
kines/chemokines were measured in
plasma and peritoneal lavage fluid of
10-week-old male mice (C57/B16)
following intraperitoneal injection of
LTA or LPS (250 lg), and in super-
natants of murine J774.2 cells,
immortalised blood monocytes, or
isolated human monocytes treated
with LTA or LPS (0–10 lg/ml). The
role of cytokine/chemokine messen-
ger RNA (mRNA) stability versus
nuclear factor-kappaB (NF-jB) and
activator protein-1 (AP-1) in mediat-
ing cytokine/chemokine release in
J774 cells was also assessed.
Results: In mice, plasma levels of
keratinocyte-derived chemokine
(KC), macrophage inflammatory
protein (MIP)-2, interleukin (IL)-10,
interferon (IFN)-c and tumour necro-
sis factor-alpha (TNF-a) and
peritoneal lavage fluid levels of KC,
MIP-2 and TNF-a increased signifi-
cantly 1 h after LPS. Only KC and
MIP-2 levels increased 1 h after LTA.
LPS-treated (10 lg/ml) J774 cells
released MIP-2, IL-10, IFN-c and
TNF-a but not KC (24 h), whereas
cells treated with 10 lg/ml LTA
released only MIP-2. LPS-stimulated
human monocytes released IL-10 and
IL-8 (24 h); by contrast, LTA-treated
cells released only IL-8. LPS and
LTA activated NF-jB and AP-1 in
J774 cells. The protein synthesis
inhibitor cycloheximide abolished
LPS-induced IL-10 mRNA expres-
sion and increased LTA- and LPS-
induced mRNA for MIP-2 in J774
cells. Conclusion: LTA and LPS, at
clinically relevant concentrations,
induced differential cytokine/chemo-
kine release in vitro and in vivo, via
effects distal to activation of NF-jB/
AP-1 that might include chromatin
remodelling or mRNA stability.
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Introduction
Sepsis and its sequelae are the leading causes of death
among critically ill patients [1]. Treatment is largely
supportive following source control and administration of
antibiotics. Sepsis is associated with uncontrolled and
excessive cytokine release. However, potential therapeu-
tic intervention targeted at cytokines has failed to reduce
mortality in multiple clinical trials [2]. These failures
likely reflect the molecular complexity and redundancy
within the inflammatory response [2] and the extent to
which an infecting organism dictates the response [3, 4].
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In this regard, distinct patterns of cytokine and leuco-
cyte gene expression have been shown for Gram-positive
and Gram-negative organisms [5] and activation of
their respective receptor pathways, Toll-like receptor
(TLR)2 and TLR4 [6]. Understanding the cellular mech-
anisms that account for these differences could,
ultimately, aid the development of novel and effective
pharmacotherapies.
Lipoteichoic acid (LTA) is a cell wall component
exclusive to Gram-positive bacteria and is shed during
bacterial replication and after antibiotic administration [7,
8]. LTA is the functional equivalent to lipopolysaccharide
(LPS), the major cell wall component of Gram-negative
bacteria. Whilst numerous in vivo studies have shown
that LPS triggers cytokine release in rodent models and
humans, fewer studies have investigated the effects of
LTA in vivo [9–11].
The aims of the present study are fourfold: first, to
compare in a rodent model the effects of intraperitoneal
(ip) LTA and LPS on release of the cytokines TNF-a,
interferon (IFN)-c and interleukin (IL)-10, and also the
CXC neutrophil chemokines, macrophage inflammatory
protein (MIP)-2 and keratinocyte-derived chemokine
(KC). Secondly, to measure cytokine/chemokine release
from the murine J774.2 monocyte/macrophage cell line
following exposure to LPS or LTA. Thirdly, to measure,
in LPS- and LTA-activated human monocytes, release of
IL-10 and IL-8, a human CXC chemokine analogous to
MIP-2/KC. Finally, we investigated mechanisms medi-
ating release of these cytokines/chemokines by examining
the activation of cell signalling moieties relevant to the
process.
Materials and methods
Bacterial products
LPS from Escherichia coli (O55:B5) was re-purified
before use [12] and quantified using the Limulus amoe-
bocyte lysate assay (BioWhitaker, Belgium). Pure LTA
was extracted in butanol at room temperature from
Staphylococcus aureus (S. aureus, serotype DSM 2033,
gift from Prof. T. Hartung, University of Konstanz). The
method of extraction is key, since hot phenol extraction of
LTA strips the native molecule of its alanine residues and
biological activity [13, 14]. Ligands were screened for
purity using primary human embryonic kidney cells sta-
bly transfected with tlr4 or tlr2/6 (data not shown).
Murine model
Ten-week-old mice (C57/B16) were housed under spe-
cific, pathogen-free conditions and used in experiments
performed using UK licensing agreements. After intra-
peritoneal administration of vehicle, LPS, or LTA, the
peritoneal cavity was lavaged using ice-cold phosphate-
buffered saline. Blood was obtained via the inferior vena
cava.
Cell culture
The murine monocyte/macrophage cell line J774.2
(referred to as J774 cells) was cultured as described pre-
viously [15].
Human peripheral blood monocytes
Blood was taken according to a Local Research Ethics
Committee-approved protocol. Monocytes were separated
from granulocytes using discontinuous Percoll density
gradient (55%, 68% and 81%) centrifugation and an
indirect magnetic labelling system (Monocyte Isolation
Kit II; Miltenyi Biotec, Germany).
Cytokine assays
A multiplex immunoassay was established to measure
multiple soluble analytes in small quantities (50 ll) of
murine plasma, lavage fluid or cell culture supernatants.
Standard concentrations of cytokine/chemokine were
used to calibrate the assay and cytokine concentrations
calculated from Alexa 488 measurements. For samples
employing human cells, cytokine assays were performed
using commercial enzyme-linked immunosorbent assays
(ELISAs; R & D Systems Europe Ltd, UK).
Quantitative RT-PCR analysis
mRNA transcript levels for IL-10 and MIP-2 were eval-
uated using quantitative reverse-transcription polymerase
chain reaction (RT-PCR) and a Rotor-Gene 3000TM
four-channel multiplex system. IL-10 and MIP-2 mRNA
levels were measured and expressed as a ratio to the
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
reference gene.
Transcription factor activity ELISA measurements
Nuclear extracts of J774 cells were prepared, and ELISA-
based kits (TransAM; ActiveMotif, Belgium) used to
assess NF-jB p50 and p65 and AP-1 c-Jun binding
activity. Results were expressed as optical density (OD)405
per milligram protein. J774 cells were also assessed for
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nuclear translocation of p65, p50 and c-Jun using immuno-
fluorescence staining and confocal microscopy [see Elec-
tronic Supplementary Material (ESM)].
Experimental protocols
In mice, LPS (250 lg, *10 mg/kg), LTA (250 lg,
*10 mg/kg) or an equivalent volume of sterile 0.9%
saline vehicle (250 ll) was administered intraperitone-
ally. The dose of LPS used equated to the mid-point of
those used by other investigators [16–18]. An identical
dose of LTA was employed, as LPS and LTA have
similar potency assessed using MIP2 release from J774
cells as an endpoint. We have previously shown LTA to
have biological activity in vivo at a dose of *4 mg/kg
[13]. Animals were euthanised 0, 1, 3 or 6 h later. Sub-
sequently, TNF-a, IFN-c and IL-10, MIP-2 and KC were
measured using the multiplexed assay in peritoneal lavage
and plasma. In parallel studies, J774 cells were activated
with LPS (0–10 lg/ml) or LTA (0–10 lg/ml) and the
same cytokines/chemokines measured in cell culture
supernatants at 24 h (for justification of doses see ESM).
The mRNA transcript levels for IL-10 and MIP-2 were
also evaluated at 4 h. Human peripheral blood monocytes
were stimulated with LPS (0–10 lg/ml) and LTA
(0–20 lg/ml) and an equivalent chemokine (IL-8) and IL-
10 assayed, again at 24 h.
To investigate whether differences in activation of the
transcription factors NF-jB and AP-1 might contribute to
differences identified in LPS- and LTA-induced MIP-2
and IL-10 release, J774 cells were incubated for 1 h with
medium, LPS (3 lg/ml) or LTA (10 lg/ml), or TNF-a
and IFN-c (as controls) prior to quantification of activated
transcription factors (and immuno-fluorescent staining;
see ESM). Also, chemokine and cytokine release was
assessed after pharmacological inhibition of the AP-1
pathway with the c-Jun N-terminal kinase (JNK) inhibitor
(see ESM). Finally, to investigate the possible contribu-
tion of stabilising/destabilising proteins to mRNA
transcript levels for IL-10 and MIP-2, de novo protein
synthesis was inhibited using cycloheximide (CXH,
0.1 lg/ml) administered for 10 min prior to the addition
of LPS or LTA.
Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM) of n experiments. Statistical analysis was
carried out using one-way analysis of variance (ANOVA)
followed by a Dunnett’s post test unless otherwise stated.
Data were log transformed for in vivo experiments before
analysis due to disparate inter-group variances. Results
were deemed significant for p \ 0.05.
Results
LTA and LPS induce different patterns
of cytokine/chemokine release in mice
There were no deaths in either the LPS or LTA groups.
LPS (250 lg ip) significantly increased plasma and peri-
toneal lavage fluid levels of MIP-2 and KC at 1, 3 and
6 h. LTA (250 lg ip) also significantly increased perito-
neal lavage fluid and plasma levels of MIP-2 and KC,
albeit only at 1 h and to a lesser extent than LPS (Fig. 1).
Whilst plasma levels of cytokines increased signifi-
cantly following LPS injection (250 lg ip) (specifically,
TNF-a, IFN-c and IL-10 by 1 h, IFN-c also at 6 h, and IL-
10 at 3 and 6 h), the direction of change in peritoneal
lavage fluid levels after LPS injection depended on the
cytokine (Fig. 1). Thus, TNF-a levels increased signifi-
cantly at 1 h following LPS (and also at 6 h in the control
group), IL-10 decreased significantly compared with sal-
ine control at 1 and 3 h, and changes in IFN-c levels were
not statistically significant. LTA (250 lg ip) had no
measurable effects on cytokine levels in plasma or peri-
toneal lavage (Fig. 1).
LTA and LPS induce different patterns
of cytokine/chemokine release in cultured monocytes
LPS (0–10 lg/ml) caused a significant release of MIP-2
(a CXC chemokine), TNF-a and IFN-c, a significant
release of IL-10 with LPS at 10 lg/ml, but no release of
another CXC chemokine KC (Fig. 2). LTA (1–10 lg/ml)
induced MIP-2 release but had no effect on KC, TNF-a,
IFN-c or IL-10 release (Fig. 2). Co-administration of LPS
(0.1 lg/ml) with LTA facilitated IL-10 release, whereby
increasing concentrations of LTA induced increasing
amounts of IL-10 (Fig. 2). Zymosan, another putative
TLR2 agonist, induced MIP-2 release from J774 cells but
had no effect on KC, TNF-a, IFN-c or IL-10 release (data
not shown). The effects of LPS and LTA on MIP-2
release were paralleled in isolated human monocytes. LPS
(0.1–10 lg/ml) and LTA (1–20 lg/ml) induced signifi-
cant and similar release of IL-8. LPS induced IL-10
release, but LTA had no effect (Fig. 3).
LTA and LPS increase active nuclear p65
and c-Jun in J774 cells
LPS (3 lg/ml) and LTA (10 lg/ml) significantly
increased nuclear binding activity of p65 and c-Jun at 1 h
as assessed using TransAm transcription factor binding
assays and when compared with transcription factor
activity of subunits extracted from untreated cells
(Fig. 4). LTA and LPS also increased nuclear transloca-
tion of p65 and c-Jun, and JNK and inhibitor of kappaB
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kinase-b (IKK-b) inhibitors reduced LTA- and LPS-
induced chemokine/cytokine release in J774 cells (see
ESM).
Contrasting effects of cycloheximide on IL-10
and MIP-2 mRNA in J774 cells
Pre-treatment (10 min) of J774 cells with CXH (0.1 lg/ml)
abolished LPS-induced IL-10 mRNA (4 h) production,
whereas the lack of effect of LTA on IL-10 mRNA was
not altered (Fig. 5). By contrast, LPS and LTA increased
MIP-2 mRNA in J774 cells and each was further
increased with CXH (Fig 5).
Discussion
Our study shows differences in expression of cytokine/
chemokine release, in vitro and in vivo, in response to
LPS compared with LTA, at clinically relevant concen-
trations. Thus, ip injection of 10 mg/kg LPS into mice
increased plasma and peritoneal lavage fluid levels of
MIP-2, KC and TNF-a. The cytokines IL-10 and IFN-c
increased in peritoneal lavage only. By contrast, ip
injection of 10 mg/kg LTA only increased levels of
plasma and peritoneal KC and MIP-2, and to a lesser
extent than LPS. LPS resulted in a fall in plasma IL-10; it
is not known whether this relates to decreased basal
production, increased elimination or dilution by intra-
vascular fluid shifts. It is possible that the reduction in this
anti-inflammatory cytokine may in part contribute to the
increase in MIP-2, KC, TNF-a and IFN-c.
LPS induced release from J774 cells of MIP-2 and
TNF-a with 0.031 lg/ml, IFN-c with 0.1 lg/ml, IL-10
with 10 lg/ml LPS, and IL-8 and IL-10 from human
monocytes with 0.1 and 1 lg/ml LPS, respectively. By
contrast, LTA (0.3–10 lg/ml) only induced MIP-2 release
from J774 cells and IL-8 from human monocytes (using
1–20 lg/ml LTA). Despite these differences, LPS and
LTA both induced NF-jB and AP-1 nuclear translocation
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Fig. 1 LTA and LPS cause different profiles of cytokine/chemo-
kine release in mice than LPS. Concentrations of MIP and KC or of
TNF-a, IFN-c and IL-10 were measured in plasma and peritoneal
lavage fluid at 0, 1, 3 and 6 h after intraperitoneal injection of saline
vehicle (250 ll, control), LPS (250 lg) or LTA (250 lg). Data are
presented as mean ± SEM from 4–6 independent experiments,
each conducted in a separate animal with individually prepared
experimental stimuli. Some time points represent only four data
points because occasional loss of multiplexing beads during
immunoassay meant data were not available. Data were log
transformed prior to analysis due to disparate inter-group variances.
*p\ 0.05, **p\ 0.01 compared with t = 0 and analysed by one-
way ANOVA with Dunnett’s post test
c
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and activity in J774 cells (at 3 and 10 lg/ml, respec-
tively), and inhibitors of these signalling pathways
reduced cytokine/chemokine release (ESM). At the
mRNA level, we showed that CXH, an inhibitor of
de novo protein synthesis, enhanced LPS- and LTA-
induced MIP-2 mRNA, abolished LPS-induced IL-10
mRNA, but did not override the lack of effect of LTA on
IL-10 mRNA. These novel findings suggest that CXH-
sensitive regulatory proteins operative at the level of
mRNA, rather than disparity in NF-jB and AP-1
Fig. 2 LTA and LPS cause different profiles of cytokine/chemo-
kine release in J774 cells. Concentrations of MIP, KC, TNFa, IFN-c
and IL-10 were measured in cell supernatants at 24 h following
exposure to LPS (0.03–10 lg/ml) or LTA (0.03–10 lg/ml), and IL-
10 after exposure to LTA (0.03–10 lg/ml) plus LPS (0.1 lg/ml).
Data are presented as mean ± SEM of three separate experiments.
*p \ 0.05, **p \ 0.01 compared with medium alone (0) and
analysed by one-way ANOVA with Dunnett’s post test, or
**p \ 0.01 between equivalent bars in groups with a line above
when analysed by two-way ANOVA
328
translocation/activation, might, at least in part, account
for differences in LPS- and LTA-induced cytokine/che-
mokine expression.
The more extensive effects on chemokine/cytokine
induction, in vivo, of LPS compared with LTA that we
have shown reflect findings of others [10, 19]. Intranasal
administration of LTA produced lower KC and MIP-2
levels in bronchoalveolar lavage fluid of mice at 6 h,
compared with LPS [10]. Also, instillation of LPS, but not
LTA, into lungs of healthy volunteers increased chemo-
kine/cytokine levels at 6 h [9, 19]. The inability of LTA to
induce IFN-c, in vivo, in our study, is consistent with a
previous finding that LTA was toxic in galactosamine-
treated mice only when IFN-c was pre-administered, sug-
gesting that LTA did not induce IFN-c [20]. However, the
lack of effect of LTA on TNF-a levels in peritoneal lavage
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Fig. 3 LPS induced IL-8 and IL-10 and LTA induced IL-8 release
from isolated human monocytes. Cytokine concentrations were
measured in cell supernatants at 24 h following exposure to LPS
(0.01–10 lg/ml) or LTA (1–20 lg/ml). Data are presented as
mean ± SEM of three separate experiments. *p \ 0.05,
**p \ 0.01 compared with medium alone (0) and analysed by
one-way ANOVA with Dunnett’s post test
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Fig. 4 LPS and LTA caused nuclear activation of NF-jB and AP-
1. p65 and c-Jun binding activity in J774 cells was measured using
the TransAM commercial assay. J774 cells were treated for 1 h
with LPS (3 lg/ml) or LTA (10 lg/ml), or medium alone. HeLa
cell extract was used as a positive control (Pos). Specificity was
shown by inhibiting binding using excess oligonucleotide with a
single base pair mutation of the consensus sequence (Mut)
compared with wild-type oligonucleotide (WT). Data are presented
for five separate experiments; **p \ 0.01 compared with medium
and analysed by one-way ANOVA with Dunnett’s post test
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in our study contrasts with findings of TNF-a in broncho-
alveolar lavage fluid of mice [21–23] following LTA
administration. One explanation for the difference might
be a greater density of target cells, particularly alveolar
macrophages, in the lung compared with the peritoneum.
The profile of LPS- and LTA-induced release of
chemokines/cytokines in vivo in our study was similar to
effects in vitro. The exception was KC, which was
released, in vivo, in quantifiably similar amounts to MIP-
2 but was un-detectable in J774 cells. Others have shown
that LPS induced release of KC from J774 cells at levels
(*20 pg/ml) below the sensitivity of the assay we
employed [24]. A lack of KC induction in J774 cells
might reflect an alternative source of KC in the intra-
peritoneal model such as fibroblasts [25], rather than a
problem with immortalised J774 macrophages.
Differences in our study between LPS- and LTA-
induced cytokines in vitro concur with previous findings.
Microarray analysis of whole blood activated with LPS or
heat-killed S. aureus showed stimulus-dependent patterns
of cytokine appearance and leucocyte gene expression [5].
Another microarray study in tammar mammary epithelial
cells showed that LTA induced lower levels of pro-
inflammatory cytokines when compared with LPS [26].
Similarly, in a range of human and murine cells, LTA was
consistently less potent than LPS in causing cytokine/che-
mokine release [27]. More specifically, S. epidermidis LTA
was 100-fold less active than E. coli LPS at inducing IL-6,
TNF and IL-1 release in J774 cells [28] and LTA a less
potent inducer of IL-1 and IL-8 release from feline whole
blood [29]. The lack of effect of LTA on IL-10 release from
J774 cells in our study also concurs with previous findings
[30]. A single report showing that LTA released IL-10 from
purified human monocytes acknowledged that contamina-
tion of the LTA with LPS was a likely explanation [31].
Differences between LTA and LPS, in terms of cytokine
release, in vivo and in vitro, mirror results from clinical
studies comparing Gram-positive and Gram-negative
infections. Plasma levels of IL-10 are lower in patients with
Gram-positive compared with Gram-negative sepsis,
although not consistently [32], and IL-1, IL-6 and IL-18
levels have been reported as significantly higher [5]. Toge-
ther these studies suggest that, clinically, differences in
cytokine release are dependent on the nature of the infection.
Differences in cytokine/chemokine release, in vivo
and in vitro, could not, at least in our study, be explained
in terms of differences in activation of key elements of
canonical inflammatory signalling pathways, specifically
NF-jB and AP-1. As others have before, we showed
equipotent induction of NF-jB with LPS and LTA [27].
NF-jB activation in monocyte/macrophages with LPS
and LTA is well recognised [33], as is LPS activation of
AP-1 [34]. Whilst LTA activation of AP-1 in human
synovial fibroblasts has been shown [35], to our knowl-
edge, ours is the first study to show activation of AP-1 in
monocytes with pure LTA. Pharmacological inhibition of
NF-jB and AP-1 implicated these pathways in MIP-2 and
IL-10 release (ESM). The lack of effect of AP-1 inhibi-
tion on LPS-induced MIP-2 release contrasts with a
previous finding that showed SP600125 inhibited MIP-2
release from RAW 264.7 cells, a monocyte cell line [36].
The difference might, at least in part, be explained by our
inability to use SP600125 above 10 lM because of
cytotoxic effects in J774 cells.
That LTA did not induce IL-10 release from either
J774 cells or human monocytes when it activated NF-jB
and AP-1, pathways linked to IL-10 release, prompted us
to measure IL-10 mRNA levels in J774 cells. The finding
that LPS, but not LTA, induced IL-10 mRNA expression,
mirroring differences in protein release, gave rise to a
number of speculations. First an, as yet, unidentified
transcription factor might contribute to LPS-induced
effects. Against this, the physical size of the transcription
factor complex already known to contain AP-1, NF-jB,
specificity protein-1 (Sp-1), general transcription factors
and RNA polymerase II could rule this out. Alternatively,
LPS but not LTA could influence pathways that impact on
either the generation of mRNA or its stability. The finding
that CXH abolished LPS-induced IL-10 mRNA suggests
that CXH-sensitive proteins facilitated transcription of or
stabilised IL-10 mRNA, evidently being proteins that
LTA could not induce. By contrast, CXH super-induction
of LTA- and LPS-induced MIP-2 mRNA suggests that
these stimuli induced proteins that either limit transcrip-
tion or reduce the stability of mRNA. However, our
experiments are unable to show whether the effect is pre-
or post-transcriptional. In this regard, others showed that
LPS stimulation was associated with nucleosome/chro-
matin remodelling at the IL-12 p40 promoter [37], an
event necessary for transcription factor binding and sub-
sequent transcription. Alternatively, we have shown
previously that LTA can have a post-transcriptional
effect, reducing IL-8 mRNA half-life in human endothe-
lial cells [38]. In support of an effect at the mRNA level is
the observation that co-administration of LTA and LPS
resulted in greater IL-10 production. We propose that
greater understanding of the nature of cytokine regulation
at the mRNA level and the similarities and dissimilarities
between Gram-positive and Gram-negative stimuli, at this
juncture, might well provide novel therapeutic and more
targeted avenues for treatment of sepsis in the future.
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